We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04188964
Recruitment Status : Active, not recruiting
First Posted : December 6, 2019
Last Update Posted : October 5, 2022
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development Ltd

Tracking Information
First Submitted Date  ICMJE November 25, 2019
First Posted Date  ICMJE December 6, 2019
Last Update Posted Date October 5, 2022
Actual Study Start Date  ICMJE February 26, 2020
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 2, 2021)
To assess the safety and tolerability of Burosumab in paediatric subjects with X-linked Hypophosphatemia (XLH) starting treatment below 12 months of age [ Time Frame: From Baseline to scheduled time points (measured throughout the study up to Week 48). ]
Incidence, frequency, and severity of adverse events (AEs) and serious AEs (SAEs), including clinically significant changes in laboratory, physical examinations, vital signs, ECGs and imaging assessments
Original Primary Outcome Measures  ICMJE
 (submitted: December 3, 2019)
Safety and tolerability of burosumab will be measured in subjects with XLH starting treatment below 12 months of age by studying the number, severity and relatedness of Adverse Events (including laboratory and imaging assessments). [ Time Frame: From baseline, measured throughout the study up to Week 64. ]
Incidence, frequency, and severity of AEs and SAEs, including clinically significant changes in laboratory assessments as well as ECHO, ECG, ultrasound and X-Ray images.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 2, 2021)
  • To characterize the pharmacokinetics (PK) of Burosumab following subcutaneous (SC) injection in paediatric subjects with XLH below 12 months of age. [ Time Frame: Measured throughout the study up to Week 48 ]
    Burosumab serum concentrations and PK parameters, including apparent clearance (CL/F), apparent volume of distribution (V/F), area under the serum concentration-time curve (AUC), maximum serum drug concentration (Cmax) and other parameters, as appropriate.
  • To characterize the effect of Burosumab on serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) in paediatric subjects with XLH starting treatment below 12 months of age [ Time Frame: Change from Baseline at Week 20, 26, 32, 40 and 48 ]
    Changes in serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D)
  • To assess the clinical effects of Burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: Baseline and Week 48 ]
    Change in serum alkaline phosphatase (ALP).
  • To assess the clinical effects of Burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    Appearance in radiographic appearance of rickets severity as assessed by the Radiograph Global Impression of Change (RGI-C) scoring system.
  • To assess the clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    The appearance in rickets severity assessed by total Rickets Severity Score (RSS).
  • To assess the clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    Change in lower extremity skeletal abnormalities, including genu varum and genu valgus, as determined by the RGI-C long leg score.
  • To assess the clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    Change in recumbent length in cm, height-for-age z-scores, and percentiles.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 3, 2019)
  • The number of participants showing an effect of burosumab on pharmacodynamic (PD) markers of phosphate homeostasis. [ Time Frame: Baseline, (Week 20, 32, 40, 48, 56 and 64). ]
    Number of participants with changes in serum phosphate and 1,25(OH)2D.
  • To characterize the pharmacokinetics (PK) of burosumab following subcutaneous (SC) injection. [ Time Frame: Baseline, (Day 3, 7, 11, and 14, Week 4, 6, 8, 12, 16, 40, 64) ]
    Burosumab serum concentrations and PK parameters.
  • The number of participants with change in serum ALP showing clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities. [ Time Frame: Baseline, Week 40 and 64. ]
    Change in serum ALP.
  • Growth and prevention and/or healing of rickets and skeletal deformities will be measured by comparing radiographs taken at baseline to x rays at the following timepoints: [ Time Frame: Baseline, Week 40 and 64. ]
    Change in time of appearance in radiographic appearance of rickets severity as assessed by the RGI-C scoring system.
  • Appearance in rickets severity assessed by total rickets severity score (RSS) [ Time Frame: Baseline, Week 40 and 64. ]
    Change in appearance in rickets severity assessed by total rickets severity score (RSS) a 10-point radiographic scoring method.
  • Lower extremity skeletal abnormalities, determined by the radiographic global impression of change (RGI-C) long leg score including genu varum and genu valgus, as determined by the RGI-C long leg score at Week 40 and 64. [ Time Frame: Baseline, Week 40 and 64. ]
    Change in lower extremity skeletal abnormalities, including genu varum and genu valgus, as determined by the RGI-C long leg scale score ranging from -3 (very much worse, or severe worsening of rickets) to +3 (very much better, or complete or near complete healing of rickets)
  • The number of participants with change in recumbent length. [ Time Frame: Baseline, at Week 40 and Week 64 ]
    Change in recumbent length measured in centimetres to calculate height-for age z scores, and percentiles
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
Official Title  ICMJE A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH)
Brief Summary A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Paediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)
Detailed Description

BUR-CL207 is a multicenter, open-label, non-randomized Phase 1/2 study in pediatric patients with XLH initiating treatment with burosumab at <12 months of age. The study includes a total treatment period of up to 48 weeks across 3 cohorts. Subjects will be enrolled in 2 age subgroups: (1) ≥6 months to <12 months of age, and (2) <6 months of age at initiation of burosumab treatment. Cohorts will aim to include 3 subjects per cohort depending on the starting dose of burosumab and relative response of patients to treatment as assessed by serum phosphate levels and by the treating physician (Investigator). Cohorts will commence in a staggered manner starting with Cohort 1, followed by Cohorts 2 and 3, which may start in parallel after an adequate observation period (4 weeks) in Cohort 1 and with approval from the Sponsor's Medical Monitor and the DSMB. The cohorts are defined as follows:

  • Cohort 1: pediatric subjects with XLH and hypophosphatemia (serum phosphate below the age-adjusted lower limit of normal [LLN]), and age from ≥6 months to <12 months of age at initiating treatment with burosumab with starting dose of 0.4 mg/kg.
  • Cohort 2: pediatric subjects with XLH and hypophosphatemia (serum phosphate below the age-adjusted LLN), and age from ≥6 months to <12 months of age at initiating treatment with burosumab with a starting dose of 0.8 mg/kg (upon Data Safety Monitoring Board [DSMB] confirmation).
  • Cohort 3: pediatric subjects with XLH and hypophosphatemia (serum phosphate below the age-adjusted LLN), and <6 months of age at initiating treatment with burosumab with a starting dose of 0.4 mg/kg (upon DSMB confirmation). Following enrollment of the first 3 or 4 subjects in Cohort 3, an interim population PK/PD evaluation may be performed to determine whether the starting dose for the cohort can be increased to 0.8 mg/kg.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE X-linked Hypophosphatemia (XLH)
Intervention  ICMJE Drug: Burosumab
Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
Other Names:
  • KRN23
  • Crysvita
Study Arms  ICMJE Experimental: Treatment
Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
Intervention: Drug: Burosumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: October 4, 2022)
16
Original Estimated Enrollment  ICMJE
 (submitted: December 3, 2019)
20
Estimated Study Completion Date  ICMJE April 2024
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female pediatric subjects, aged <12 months at burosumab treatment initiation.
  2. Pediatric subjects with PHEX mutation or variant of uncertain significance in either the subject or a directly related family member with appropriate X-linked inheritance.
  3. Presenting serum phosphate levels below the age-specific LLN at Screening.
  4. A legally authorized representative has provided written informed consent prior to any research-related procedures.
  5. A legally authorized representative must, in the opinion of the Investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments required by the study protocol, including providing access to prior medical records for the collection of historical growth, biochemical, and radiographic data and disease history.

Exclusion Criteria:

  1. The pediatric subject's legally authorized representative is unwilling or unable to stop the subject's treatment with oral phosphate and/or pharmacologic vitamin D metabolite or analogue (e.g. calcitriol, alfacalcidol) for at least 1 week before planned treatment start and for the duration of the study.
  2. Preterm pediatric patients (defined as born before 37 weeks of pregnancy) with a chronological age of <6 months. Enrolment of preterm pediatric patients with a chronological age ≥6 months must be confirmed by the Study Medical Monitor before study entry.
  3. Impairment of renal function measured as serum creatinine above the age-adjusted normal range and estimated GFR (calculated using the Bedside Schwartz equation) below the age-adjusted normal range.
  4. Presence of nephrocalcinosis on renal ultrasound.
  5. Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits.
  6. Presence of a concurrent disease or condition that would interfere with study participation or affect subject safety.
  7. Predisposition to infection or known immunodeficiency.
  8. Severe dermatological conditions over the available injection sites.
  9. Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  10. Metabolic bone disease, nutritional rickets and/or osteopenia of other origin than XLH at Screening and/or Baseline.
  11. Serum levels of 25-hydroxyvitamin D (25(OH)D) below the LLN that are clinically significant in the opinion of the Investigator.
  12. Evidence of any hyperparathyroidism not associated with XLH as determined by the Investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 1 Year   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   France,   Italy,   Spain,   Sweden,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04188964
Other Study ID Numbers  ICMJE BUR-CL207
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Kyowa Kirin Pharmaceutical Development Ltd
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Kyowa Kirin Pharmaceutical Development Ltd
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Kyowa Kirin Pharmaceutical Development Ltd
Verification Date October 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP